WPD Pharmaceuticals Plans to Commence Phase Ib/II Study of Berubicin for the Treatment of Glioblastoma in 2H 2021
June 28, 2021 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, June 28, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, today provided an...
WPD Pharmaceuticals Invited to Join International Research Consortium
June 10, 2021 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, June 10, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is excited to...
WPD Pharmaceuticals Provides Update on Audited Financial Statements
May 14, 2021 16:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, May 14, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company”) (CSE: WBIO) (FSE: 8SV1), provides this update on the status of the audit of its consolidated...
WPD Pharmaceuticals to Receive $6.7 Million Grant for Development of Annamycin Drug Candidate
May 11, 2021 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce...
WPD Pharmaceuticals Receives Approval for Temporary Management Cease Trade Order for Late Filing of Audited Annual Financial Statements
May 05, 2021 12:26 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, May 05, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company”) (CSE: WBIO) (FSE: 8SV1), announces that further to its news release dated April 29, 2021 it has...
WPD Pharmaceuticals Announces Application for a Management Cease Trade Order For Late Filing of Audited Annual Financial Statements
April 29, 2021 08:55 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, April 29, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company”) (CSE: WBIO) (FSE: 8SV1), the Company announces that it has made an application to the British...
WPD Pharmaceuticals to Attend the 10th Congress of the Polish Society of Pediatric Oncology and Hematology and Present Assumption of the Phase 1 Study with Berubicin in Pediatric Malignant Gliomas
April 27, 2021 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, April 27, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to...
WPD Pharmaceuticals and IAG to Host a Joint Webinar, “The Potential of Advanced Imaging to Show the Early Treatment Effects of Berubicin in Brain Cancer”
April 13, 2021 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, April 13, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to...
WPD Pharmaceuticals Holds Pre-Submission Meeting with the European Medicines Agency and Receives Second Prepayment of C$954,248 From a Total C$7.4 Million Grant for Development of Berubicin
April 06, 2021 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, April 06, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to...
WPD Pharmaceuticals Announces Amended Sublicense Agreement with Moleculin Biotech for WP1066, WP1122 and Annamycin Drug Candidates
March 30, 2021 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, March 30, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (“WPD” or the “Company”) (CSE: WBIO) (FSE: 8SV1), a clinical stage pharmaceutical company, is pleased to...